KAZIA THERAPEUTICS LTD (KZIA) Form 424B3 — Sep 18, 2026

Kazia Therapeutics filed a prospectus supplement on September 18, 2026 covering 10,700,211 American Depositary Shares representing 5,350,105,500 ordinary shares, updating its December 23, 2025 prospectus with a same-day Form 6-K. The 6-K discloses that Kazia appointed JPMorgan Chase Bank, N.A. as sole depositary for its ADR program, replacing BNY Mellon, under a Second Amended and Restated Deposit Agreement in which each ADS represents 500 ordinary shares. JPMorgan has filed a Form F-6 registration statement for the new ADR program.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.